A model for predicting response to PD-1 inhibitors in NSCLC

Whole exome sequencing was used to examine the impact of human leukocyte antigen B44 in a non-small cell lung cancer cohort treated with single agent pembrolizumab with over five years of follow-up.

• Type: Cohort
• Archiver: The database of Genotypes and Phenotypes (dbGaP)